NASDAQ · Biotechnology

Neurocrine Biosciences, Inc. (NBIX) Stock

$142.44 +0.84% NASDAQ: NBIX Healthcare

Valuation

MetricValue
Price$142.44
Market Cap$14.32B
P/E Ratio20.05
P/B Ratio3.86
P/S Ratio4.21
EPS (TTM)$4.67
52-Week High$186.12
52-Week Low$122.14
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE21.13%
ROA13.16%
ROCE17.59%
Gross Margin98.17%
Operating Margin25.19%
Net Margin20.91%
Debt/Equity0.11
Current Ratio3.40

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.1B$1.5B$1.9B$2.4B$2.9B
Operating Profit$103.0M$249.0M$251.0M$571.0M$619.0M
Net Profit$90.0M$155.0M$250.0M$341.0M$479.0M
EPS$0.92$1.56$2.47$3.29$4.67
Op Margin9.0%16.7%13.3%24.2%21.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.1B$2.4B$3.3B$3.7B$4.6B
Total Liabilities$699.0M$661.0M$1.0B$1.1B$1.4B
Cash$341.0M$263.0M$251.0M$233.0M$713.0M
Borrowings$440.0M$263.0M$428.0M$455.0M$415.0M

Latest News

Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti As Chief Business Officer Simply Wall St. · Jul 22, 2026 AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program Zacks · Jul 22, 2026 Here's Why You Should Add Savara Stock to Your Portfolio Now Zacks · Jul 22, 2026 Neurocrine Biosciences Appoints Samir Siddhanti as Chief Business Officer MT Newswires · Jul 21, 2026 Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer PR Newswire · Jul 21, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$257.0M$339.0M$390.0M$595.0M$783.0M
Investing Cash Flow$-154.0M$-194.0M$-495.0M$-165.0M$-298.0M
Financing Cash Flow$0$0$0$-300.0M$-168.0M
Net Cash Flow$154.0M$-73.0M$-12.0M$-18.0M$480.0M
Free Cash Flow$233.0M$323.0M$362.0M$557.0M$749.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.20
EV / EBITDA15.55
FCF Yield6.12%
Quick Ratio1.75
Interest Coverage272.03
Return 1Y2.87%
Return 3Y24.65%
Return 5Y40.20%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACADACADIA Pharmaceuticals Inc. $19.78 +1.02% 8.87 $3.39B 0.00%
AXSMAxsome Therapeutics, Inc. $168.35 -1.02% -49.17 $8.66B 0.00%
BHVNBiohaven Ltd. $12.08 +1.26% -2.77 $1.82B 0.00%
GHRSGH Research PLC $21.11 +3.23% -22.71 $1.45B 0.00%
HLBBFH. Lundbeck A/S $6.60 +0.00% 11.50 $5.23B 2.73%

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. is led by CEO Kyle W. Gano, employs 2,000 people, headquartered in San Diego, US, publicly traded since 1996.

Neurocrine Biosciences, Inc. (NBIX) stock trades at $142.44 with a market capitalization of $14.32B. The stock is valued at a price-to-earnings (P/E) ratio of 20.05, price-to-book of 3.86, price-to-sales of 4.21. Over the past 52 weeks the stock has ranged between $122.14 and $186.12, and currently trades 23.5% below its 52-week high.

On profitability, Neurocrine Biosciences, Inc. generates a return on equity (ROE) of 21.13% — well above the market average, a sign of a high-quality business, return on capital employed of 17.59%, an operating margin of 25.19%, a net profit margin of 20.91%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides